Growing lines of evidence suggest that the neurodegenerative diseases are tightly linked to the ubiquitin and the proteasome pathway (UPP), which plays a pivotal role in selective protein degradation in the cells. Genetic mutations in the ubiquitin pathway (ie; parkin and Uchll) cause familial Parkinson's disease (PD), and sequestration of such UPP enzymes in the inclusion bodies are observed in not only sporadic forms of PD but also in other neurodegenerative diseases. These evidences place the reduction of UPP as a central mechanism underlying the pathogenesis and progression of neurodegenerative diseases linked to inclusion body formation. In addition to the UPP, autophagic pathway (AP), which is regulated by the ubiquitin-like modifier systems, attracted considerable attention as an alternative pathway to clean-up inclusion bodies in the cells. This review highlighted the recent progress in our understanding on the regulation of UPP and its cooperation with AP for the quality control of the proteins and elimination of ubiquitin positive aggregates.

Download full-text PDF

Source

Publication Analysis

Top Keywords

neurodegenerative diseases
12
protein degradation
8
inclusion bodies
8
pathway
5
upp
5
[regulation protein
4
degradation pathway
4
ubiquitin
4
pathway ubiquitin
4
ubiquitin family
4

Similar Publications

Background And Objectives: Chronic kidney disease (CKD) is known to be associated with increased plasma phosphorylated tau217 (p-tau217) concentrations, potentially confounding the utility of plasma p-tau217 measurements as a marker of amyloid pathology in individuals with suspected Alzheimer disease (AD). In this study, we quantitatively investigate the relationship of plasma p-tau217 concentrations vs estimated glomerular filtration rate (eGFR) in individuals with CKD with and without amyloid pathology.

Methods: This was a retrospective examination of data from 2 observational cohorts from either the Mayo Clinic Study of Aging or the Alzheimer's Disease Research Center cohorts.

View Article and Find Full Text PDF

Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).

View Article and Find Full Text PDF

Background And Objectives: Despite the absence of acute lesion activity in multiple sclerosis (MS), chronic neurodegeneration continues to progress, and a potential underlying mechanism could be the kynurenine pathway (KP). Prolonged activation of the KP from chronic inflammation is known to exacerbate the progression of neurodegenerative diseases through the production of neurotoxic metabolites. Among the 8 KP metabolites, six of them, namely kynurenine (KYN), 3-hydroxylkynurenine (3HK), anthranilic acid (AA), kynurenic acid (KYNA), and quinolinic acid (QUIN), have been associated with neurodegeneration.

View Article and Find Full Text PDF

Tail Anchored protein insertion mediated by CAML and TRC40 links to neuromuscular function in mice.

PLoS Genet

January 2025

Department of Pediatric and Adolescent Medicine, Mayo Clinic, 200 1st St. SW, Rochester, Minnesota 55905, United States of America.

Motor neuron diseases, such as amyotrophic lateral sclerosis (ALS) and progressive bulbar palsy, involve loss of muscle control resulting from death of motor neurons. Although the exact pathogenesis of these syndromes remains elusive, many are caused by genetically inherited mutations. Thus, it is valuable to identify additional genes that can impact motor neuron survival and function.

View Article and Find Full Text PDF

Enhancing protein O-GlcNAcylation by pharmacological inhibition of the enzyme O-GlcNAcase (OGA) has been considered as a strategy to decrease tau and amyloid-beta phosphorylation, aggregation, and pathology in Alzheimer's disease (AD). There is still more to be learned about the impact of enhancing global protein O-GlcNAcylation, which is important for understanding the potential of using OGA inhibition to treat neurodegenerative diseases. In this study, we investigated the acute effect of pharmacologically increasing O-GlcNAc levels, using the OGA inhibitor Thiamet G (TG), in normal mouse brains.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!